Compare CWBC & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CWBC | AGMB |
|---|---|---|
| Founded | 1989 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 729.1M | 738.7M |
| IPO Year | 2000 | 2024 |
| Metric | CWBC | AGMB |
|---|---|---|
| Price | $25.81 | $13.25 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 3 |
| Target Price | $28.63 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 241.3K | 89.6K |
| Earning Date | 04-23-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.03% | N/A |
| EPS Growth | ★ 344.44 | N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.58 | N/A |
| Revenue Next Year | $17.64 | $17.86 |
| P/E Ratio | $42.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $19.79 | $8.75 |
| 52 Week High | $28.17 | $17.82 |
| Indicator | CWBC | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 54.69 | 51.22 |
| Support Level | $24.75 | $9.54 |
| Resistance Level | $27.95 | $14.19 |
| Average True Range (ATR) | 0.50 | 1.00 |
| MACD | 0.08 | -0.11 |
| Stochastic Oscillator | 84.21 | 20.53 |
Community West Bancshares is a bank holding company whose principal business is to serve as the holding company for its wholly-owned subsidiary Community West Bank N.A. Through CWB, the company provides a variety of financial products and full-service Banking Centers within California's Greater Sacramento, San Joaquin Valley, and Central Coast regions, that provide Commercial Lending, Real Estate, Agribusiness, Private Banking, and Cash Management Departments. The company has one reportable segment: Banking operations. Loans and leases, investment securities, interest-bearing deposits and non-interest income provide the revenues of the banking operation.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.